Bio-Rad Laboratories (BIO)
Bio-Rad Laboratories on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as laboratory analytical instruments.
1.2M
Short interest
settlement 2026-09-30
4.3
Days to cover
+0.4 days vs prior
62.5%
Short share of volume
2026-10-09
400
Fails to deliver
settlement 2026-09-14
Wed 28 Oct
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in BIO is 1,182,765 shares, up 52,467 shares over the last month. Over the last 48 readings it ranged from 488,574 shares (29 November 2024) to 1,559,452 shares (15 July 2026). At the reported average volume of 277K shares a day that is 4.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bio" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1,182,765 | +18.4% | 276,887 | 4.27 |
| 2026-09-15 | 998,654 | -11.7% | 260,959 | 3.83 |
| 2026-08-31 | 1,130,298 | -14.9% | 266,609 | 4.24 |
| 2026-08-14 | 1,327,739 | -6.0% | 275,201 | 4.82 |
| 2026-07-31 | 1,412,268 | -9.4% | 329,435 | 4.29 |
| 2026-07-15 | 1,559,452 | +2.8% | 261,563 | 5.96 |
| 2026-06-30 | 1,517,121 | -0.3% | 372,136 | 4.08 |
| 2026-06-15 | 1,521,346 | +1.0% | 347,408 | 4.38 |
| 2026-05-29 | 1,506,093 | +12.3% | 577,789 | 2.61 |
| 2026-05-15 | 1,340,805 | +22.8% | 459,353 | 2.92 |
| 2026-04-30 | 1,091,991 | +2.3% | 295,806 | 3.69 |
| 2026-04-15 | 1,067,080 | -12.1% | 250,465 | 4.26 |
| 2026-03-31 | 1,214,228 | +20.5% | 357,785 | 3.39 |
| 2026-03-13 | 1,008,034 | +6.4% | 266,141 | 3.79 |
| 2026-02-27 | 947,436 | -0.3% | 307,535 | 3.08 |
| 2026-02-13 | 950,646 | +16.1% | 333,125 | 2.85 |
| 2026-01-30 | 819,074 | +3.4% | 245,022 | 3.34 |
| 2026-01-15 | 792,425 | -8.3% | 223,782 | 3.54 |
| 2025-12-31 | 864,116 | -3.9% | 164,537 | 5.25 |
| 2025-12-15 | 898,989 | -9.0% | 161,888 | 5.55 |
| 2025-11-28 | 987,606 | +13.8% | 176,594 | 5.59 |
| 2025-11-14 | 867,843 | -6.8% | 166,301 | 5.22 |
| 2025-10-31 | 931,212 | -16.7% | 318,214 | 2.93 |
| 2025-10-15 | 1,118,321 | +34.1% | 190,059 | 5.88 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of BIO volume is 62.5%, down 14.5 points over the last five sessions. Over the last 30 readings it ranged from 40.0% (15 September 2026) to 87.1% (9 September 2026). The latest reading is 4.4 points below the 30-session average of 67.0%, on 55K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 35K | 55K | 62.5% | 3 |
| 2026-10-08 | 98K | 125K | 78.6% | 0 |
| 2026-10-07 | 93K | 117K | 79.7% | 0 |
| 2026-10-06 | 46K | 63K | 72.9% | 1 |
| 2026-10-05 | 69K | 110K | 62.6% | 0 |
| 2026-10-02 | 56K | 73K | 77.0% | 28 |
| 2026-10-01 | 59K | 103K | 57.2% | 1,511 |
| 2026-09-30 | 58K | 77K | 74.9% | 0 |
| 2026-09-29 | 110K | 126K | 86.6% | 3 |
| 2026-09-28 | 40K | 82K | 48.4% | 0 |
| 2026-09-25 | 53K | 89K | 59.3% | 0 |
| 2026-09-24 | 85K | 147K | 57.6% | 385 |
| 2026-09-23 | 43K | 67K | 64.1% | 0 |
| 2026-09-22 | 145K | 172K | 84.2% | 0 |
| 2026-09-21 | 56K | 88K | 63.8% | 0 |
| 2026-09-18 | 54K | 90K | 59.4% | 0 |
| 2026-09-17 | 51K | 92K | 55.9% | 1 |
| 2026-09-16 | 55K | 100K | 55.0% | 27 |
| 2026-09-15 | 84K | 210K | 40.0% | 0 |
| 2026-09-14 | 71K | 111K | 63.7% | 0 |
| 2026-09-11 | 65K | 163K | 40.1% | 0 |
| 2026-09-10 | 63K | 110K | 57.6% | 18 |
| 2026-09-09 | 61K | 70K | 87.1% | 19,789 |
| 2026-09-08 | 37K | 50K | 74.4% | 0 |
| 2026-09-04 | 25K | 32K | 77.6% | 0 |
| 2026-09-03 | 42K | 50K | 83.8% | 0 |
| 2026-09-02 | 96K | 112K | 86.0% | 15,604 |
| 2026-09-01 | 82K | 119K | 69.2% | 1 |
| 2026-08-31 | 45K | 78K | 56.8% | 0 |
| 2026-08-28 | 60K | 83K | 73.0% | 40 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in BIO is 400 shares, down 1,661 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (15 April 2026) to 90,159 shares (31 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 400 | $369.32 | $148K |
| 2026-09-10 | 2,061 | $376.97 | $777K |
| 2026-09-08 | 3 | $386.11 | $1K |
| 2026-09-03 | 4,193 | $388.51 | $1.6M |
| 2026-08-25 | 17,170 | $381.76 | $6.6M |
| 2026-08-18 | 13,658 | $355.23 | $4.9M |
| 2026-08-11 | 102 | $354.54 | $36K |
| 2026-08-05 | 6,024 | $332.88 | $2.0M |
| 2026-07-27 | 563 | $314.46 | $177K |
| 2026-07-24 | 300 | $316.38 | $95K |
| 2026-07-21 | 6,340 | $301.90 | $1.9M |
| 2026-07-10 | 36 | $297.28 | $11K |
| 2026-07-08 | 524 | $292.50 | $153K |
| 2026-06-30 | 23 | $295.30 | $7K |
| 2026-06-22 | 281 | $282.44 | $79K |
| 2026-06-16 | 25 | $289.28 | $7K |
| 2026-06-04 | 15 | $304.83 | $5K |
| 2026-05-20 | 622 | $281.05 | $175K |
| 2026-05-14 | 555 | $243.51 | $135K |
| 2026-05-12 | 18 | $243.79 | $4K |
| 2026-05-07 | 208 | $259.02 | $54K |
| 2026-05-01 | 20 | $280.12 | $6K |
| 2026-04-21 | 1,274 | $303.34 | $386K |
| 2026-04-20 | 24 | $299.02 | $7K |
| 2026-04-15 | 2 | $292.23 | $584 |
| 2026-04-09 | 10 | $281.15 | $3K |
| 2026-04-08 | 7 | $278.00 | $2K |
| 2026-04-07 | 2,351 | $278.85 | $656K |
| 2026-03-31 | 90,159 | $270.36 | $24.4M |
| 2026-03-26 | 639 | $273.60 | $175K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for BIO in the last 90 days. The most recent filings are listed below. Latest filing: ENGELHARDT EVA ANETTE (EVP, President, CDG) on 2026-09-06.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-06 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Tax withholding | 485 | $386.11 | $187K | 2K |
| 2026-09-06 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 1K | $0.00 | $0 | 2K |
| 2026-09-06 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Tax withholding | 305 | $386.11 | $118K | 2K |
| 2026-09-06 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 768 | $0.00 | $0 | 2K |
| 2026-09-06 | EVRAN SEDAT | EVP, Global Supply Chain | Tax withholding | 277 | $386.11 | $107K | 4K |
| 2026-09-06 | EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 864 | $0.00 | $0 | 4K |
| 2026-09-06 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 782 | $386.11 | $302K | 4K |
| 2026-09-06 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 2K | $0.00 | $0 | 5K |
| 2026-09-06 | SCHWARTZ NORMAN D | Chairman & CEO | Tax withholding | 2K | $386.11 | $716K | 449K |
| 2026-09-06 | SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 3K | $0.00 | $0 | 451K |
| 2026-09-06 | BARRY JAMES | EVP, President, LSG | Tax withholding | 470 | $386.11 | $181K | 2K |
| 2026-09-06 | BARRY JAMES | EVP, President, LSG | Option exercise | 1K | $0.00 | $0 | 2K |
| 2026-09-06 | Allison Schwartz | Director | Tax withholding | 34 | $386.11 | $13K | 2K |
| 2026-09-06 | Allison Schwartz | Director | Option exercise | 92 | $0.00 | $0 | 2K |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Tax withholding | 504 | $386.11 | $195K | 1K |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Option exercise | 1K | $0.00 | $0 | 2K |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Tax withholding | 233 | $386.11 | $90K | 366 |
| 2026-09-05 | Mehta Rajat | EVP, GBL Commercial Operations | Option exercise | 456 | $0.00 | $0 | 599 |
| 2026-09-05 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Tax withholding | 369 | $386.11 | $142K | 1K |
| 2026-09-05 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 1K | $0.00 | $0 | 2K |
| 2026-09-05 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Tax withholding | 246 | $386.11 | $95K | 1K |
| 2026-09-05 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 685 | $0.00 | $0 | 1K |
| 2026-09-05 | EVRAN SEDAT | EVP, Global Supply Chain | Tax withholding | 329 | $386.11 | $127K | 3K |
| 2026-09-05 | EVRAN SEDAT | EVP, Global Supply Chain | Option exercise | 1K | $0.00 | $0 | 3K |
| 2026-09-05 | DiVincenzo Jonathan P. | President & COO | Tax withholding | 668 | $386.11 | $258K | 2K |
| 2026-09-05 | DiVincenzo Jonathan P. | President & COO | Option exercise | 2K | $0.00 | $0 | 3K |
| 2026-09-05 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 559 | $386.11 | $216K | 3K |
| 2026-09-05 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 1K | $0.00 | $0 | 4K |
| 2026-09-05 | SCHWARTZ NORMAN D | Chairman & CEO | Tax withholding | 3K | $386.11 | $1.1M | 447K |
| 2026-09-05 | SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 4K | $0.00 | $0 | 450K |
| 2026-09-05 | BARRY JAMES | EVP, President, LSG | Tax withholding | 369 | $386.11 | $142K | 1K |
| 2026-09-05 | BARRY JAMES | EVP, President, LSG | Option exercise | 1K | $0.00 | $0 | 2K |
| 2026-09-05 | Allison Schwartz | Director | Tax withholding | 82 | $386.11 | $32K | 2K |
| 2026-09-05 | Allison Schwartz | Director | Option exercise | 228 | $0.00 | $0 | 2K |
| 2026-09-01 | SCHWARTZ NORMAN D | Chairman & CEO | Tax withholding | 2K | $380.96 | $890K | 446K |
| 2026-09-01 | SCHWARTZ NORMAN D | Chairman & CEO | Option exercise | 5K | $0.00 | $0 | 449K |
| 2026-09-01 | BARRY JAMES | EVP, President, LSG | Tax withholding | 154 | $380.96 | $59K | 781 |
| 2026-09-01 | BARRY JAMES | EVP, President, LSG | Option exercise | 425 | $0.00 | $0 | 935 |
| 2026-09-01 | Allison Schwartz | Director | Tax withholding | 43 | $380.96 | $16K | 2K |
| 2026-09-01 | Allison Schwartz | Director | Option exercise | 117 | $0.00 | $0 | 2K |
| 2026-07-25 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Tax withholding | 89 | $314.46 | $28K | 503 |
| 2026-07-25 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Option exercise | 246 | $0.00 | $0 | 592 |
| 2026-05-11 | ENGELHARDT EVA ANETTE | EVP, President, CDG | Sell | 550 | $246.54 | $136K | 346 |
| 2026-04-24 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Tax withholding | 77 | $287.84 | $22K | 750 |
| 2026-04-24 | ENLOE COURTNEY C | EVP, General Counsel & Sec | Option exercise | 186 | $0.00 | $0 | 827 |
| 2026-04-24 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Tax withholding | 420 | $287.84 | $121K | 3K |
| 2026-04-24 | Lakkaraju Roop Kalyan | EVP, Chief Financial Officer | Option exercise | 1K | $0.00 | $0 | 3K |
| 2026-04-21 | PEI MELINDA LITHERLAND | Director | Option exercise | 407 | $0.00 | $0 | 715 |
| 2026-04-21 | PINKSTON ARNOLD A | Director | Option exercise | 407 | $0.00 | $0 | 715 |
| 2026-04-21 | Hinckley Greg K | Director | Option exercise | 407 | $0.00 | $0 | 1K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for BIO worth $1.0M at the prices reported; 0 in the last 90 days worth $0. Latest: Alles Institute for Medical Research Corp filed on 2026-05-28 to sell 700 shares ($219K) from 2026-05-28.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-05-28 | Alles Institute for Medical Research CorpDirector, 10% Stockholder | 700 | $219K | 0.003% | 2026-05-28 | Wells Fargo Clearing Services |
| 2026-05-11 | EVA ENGELHARDTOfficer | 550 | $136K | 0.003% | 2026-05-11 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-02 | MICHAEL W CROWLEYOfficer | 776 | $248K | 0.004% | 2025-12-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-18 | Alles Institute for Medical Research CorpDirector, 10% Stockholder | 760 | $229K | 0.003% | 2025-11-18 | Wells Fargo Clearing Services |
| 2025-11-06 | JAMES BARRYOfficer | 701 | $215K | 0.003% | 2025-11-06 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of BIO in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Norman D. Schwartz at 97.2% of the class (4,929,036 shares), filed 2025-10-30 for an event on 2025-09-25.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-03-26 | 13G/Ano. 13 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-10-30 | 13D/Ano. 9 | Norman D. Schwartzindividual | 4.9M | 97.2% | 2025-09-25 |
| 2025-10-30 | 13D/Ano. 9 | Steven D. Schwartzindividual | 4.1M | 80.8% | 2025-09-25 |
| 2025-10-30 | 13D/Ano. 9 | Blue Raven Partners, L.P.partnership | 4.1M | 80.1% | 2025-09-25 |
| 2025-10-30 | 13D/Ano. 9 | Alice N. Schwartz Revocable Trustother entity | 438K | 8.6% | 2025-09-25 |
| 2025-10-17 | 13G/Ano. 12 | BlackRock, Inc.parent holding company | 1.6M | 7.4% | 2025-09-30 |
13F holders
Tracked managers holding BIO at their latest 13F. JSON6 of the 30 tracked managers held BIO at their latest 13F, $134.5M in total at quarter-end prices. AQR Capital Management is the largest at $56.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 193K | $56.0M | 0.02% | +98K |
| Fisher Asset Management | 2026-06-30 | 117K | $34.3M | 0.01% | -2K |
| Citadel Advisors | 2026-06-30 | 61K | $17.9M | 0.00% | -88K |
| Millennium Management | 2026-06-30 | 60K | $17.6M | 0.01% | +57K |
| D. E. Shaw & Co. | 2026-06-30 | 19K | $5.7M | 0.00% | +11K |
| Two Sigma Investments | 2026-06-30 | 10K | $3.0M | 0.00% | -668 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Bio-Rad Laboratories reported revenue of $651.0M, down 0.1% from the same quarter a year earlier, and net income of $371.4M (13.85 diluted EPS). In FY 2025 it generated $532.2M of operating cash flow and spent $295.5M on buybacks. As of 2026-06-30, cash was $517.0M against $1.20B of debt.
- Cash
- $517.0M
- Debt
- $1.20B
- Equity
- $7.17B
- Total assets
- $10.25B
- Shares outstanding
- 27,668,031
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $651.0M | $371.4M | 57.1% | 13.85 |
| Q1 FY 2026 | 2026-03-31 | $592.1M | -$527.1M | -89.0% | -19.55 |
| Q4 FY 2025derived | 2025-12-31 | $693.2M | $720.0M | 103.9% | n/a |
| Q3 FY 2025 | 2025-09-30 | $653.0M | -$341.9M | -52.4% | -12.70 |
| Q2 FY 2025 | 2025-06-30 | $651.6M | $317.8M | 48.8% | 11.67 |
| Q1 FY 2025 | 2025-03-31 | $585.4M | $64.0M | 10.9% | 2.29 |
| Q4 FY 2024 | 2024-12-31 | n/a | -$715.8M | n/a | -25.57 |
| Q3 FY 2024 | 2024-09-30 | $649.7M | $653.2M | 100.5% | 23.34 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $2.58B | $759.9M | $532.2M | $157.6M | $295.5M | n/a |
| FY 2024 | 2024-12-31 | $2.57B | -$1.84B | $455.2M | $165.6M | $203.6M | n/a |
| FY 2023 | 2023-12-31 | $2.67B | -$637.3M | $374.9M | $156.7M | $428.7M | n/a |
| FY 2022 | 2022-12-31 | $2.80B | -$3.63B | $194.4M | $112.8M | $215.7M | n/a |
| FY 2021 | 2021-12-31 | $2.92B | $4.25B | $669.5M | $133.7M | $50.0M | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2010-06-30 from the cover page.
What this page is
Bio-Rad Laboratories in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Bio-Rad Laboratories (BIO), SEC CIK 12208, listed on NYSE, classified by the SEC as laboratory analytical instruments. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-05-28.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-03-26.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-06.JSON and CSV
- Company record
- EDGAR filing index for CIK 12208Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as laboratory analytical instruments
Other company pages
Datasets
Frequently Asked Questions
How much of BIO is sold short?
What is BIO's daily short volume?
Does BIO have fails to deliver?
Are BIO insiders buying or selling?
Have BIO insiders filed to sell?
Who owns 5% or more of BIO?
What did BIO report last quarter?
Which tracked 13F managers own BIO?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.